drugset / Trial / NCT00509431
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given together with sirolimus and to see how well they work in treating patients with recurrent malignant glioma.
Timeline
- Start
- 2006-08
- Primary completion
- 2011-12
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Sirolimus | Small molecule | 5 mg | Oral |